Lung Cancer Archives
Tobacco control could prevent more cancer deaths than any other strategy.
Significant improvements were seen with the addition of atezolizumab to CnP in stage IV non-squamous non-small cell lung cancer, regardless of patient PD-L1 status.
Most patients with metastatic non-small cell lung cancer who received targeted therapy based on plasma result achieved clinical response.
In individuals aged 18 to 35, California has had larger drops in smoking initiation, intensity, and higher rates of quitting.
Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
Researchers investigated whether the rates of immune-related adverse events linked to treatment with nivolumab or pembrolizumab were similar across 2 different cancer types.
Longer progression-free survival was significantly longer in patients with ALK-positive disease who did not previously take an ALK inhibitor.
Classifier integrates relative abundance of 2 plasma proteins with clinical risk prediction model for lung nodules.
The approval was based on data from the ARCHER 1050 open-label, active controlled study which randomized patients with unresectable, metastatic NSCLC to treatment with either dacomitinib (N=227) or gefitinib (N=225).
Salvage treatment for recurrence of early-stage non-small cell lung cancer after initial treatment with stereotactic ablative radiotherapy improved patient survival.
LOXO-292 is being evaluated in the ongoing Phase 1/2 LIBRETTO-001 clinical trial.
Serving patients' specific needs, such as referral to socioeconomic support, can improve care.
High-quality diet linked to reduced risk of overall and cancer-specific mortality vs poor-quality diet.
Physicians universally recommended lung cancer screening and rarely discuss harms.
Screening for small cell lung cancer using low-dose computed tomography had no effect on outcomes for patients.
Although screening for lung cancer with low-dose computed tomography has demonstrated a reduction in mortality, some experts say the benefits do not outweigh the potential harms.
As lung cancer screening disseminates into clinical practice, efforts designed to target black men should be prioritized.
The median OS was not reached at the time of the data cut-off in the pembrolizumab plus chemotherapy arm and was 11.3 months for those in the chemotherapy arm.
Data showed that 12% responded to treatment based on assessment by a Blinded Independent Central Review, regardless of PD-L1 expression; 11% had a partial response, and 1 patient had a complete response (0.9%).
Compared with routine genetic testing, there was no improvement in unadjusted mortality rate in non-small cell lung cancer.
From 2000 to 2015, individuals without insurance or usual care were less likely to have undergone cancer screening.
Risk score based on panel of four circulating protein biomarkers.
A Phase 2 multicenter trial examined the safety and efficacy of lurbinectedin in several types of advanced solid tumors, including SCLC.
Nurse navigators include registered nurses and licensed practical nurses who work together in pairs
Incorporating lay health workers into cancer care increases goals-of-care documentation and patient satisfaction.
Aldehydes act by inducing DNA damage and inhibiting DNA repair.
The incidence of lung cancer remains increased 5 years after smoking cessation.
ICU and hospital mortality were lower for patients with cancer vs those without cancer.
Standardized definition and guidance on estimation may facilitate understanding of cancer overdiagnosis.
Post-traumatic stress symptoms were also linked to lower risk of readmission in hospitalized patients with cancer.
Awake video-assisted thoracoscopic surgery was safe and feasible in some patients with poor lung function and lung cancer.
A history of chronic inflammatory lung disease appears to increase the risk of developing non-small cell lung cancer.
Targeted sequencing, whole-genome sequencing, and whole-genome bisulfite sequencing showed potential for detecting lung cancer.
Pembrolizumab improved overall survival vs chemotherapy regardless of the programmed death ligand 1 tumor proportion score.
A total of 8 quantitative radiologic features were used to characterize indeterminate screen-detected lung nodules.
Merck initially gained accelerated approval for Keytruda with Alimta and carboplatin in May 2017.
Researchers created a web-based decision tool to facilitate personalized discussions regarding lung cancer screening.
Researchers examined nationwide population-based incidence of lung cancer according to sex, race or ethnic group, age group, birth year, and calendar period of diagnosis.
Bioengineered tracheal and bronchial reconstruction was conducted using stented aortic matrices.
The most eligible smokers were populated in South, which had most screening sites but the low screening rates
Four models were well-calibrated and had higher areas under the curve than 5 models that overestimated lung cancer risk.
Serum CKAP4 levels of lung cancer patients were significantly higher than those of healthy controls.
Prostate and lung cancer expected to emerge as the most common types by 2030.
For clinical stage 1 non-small-cell lung cancer, 21.7% of patients upstaged after 1 week and 31.5% after 8 weeks.
More cancer survivors prescribed 5 or more unique medications, including medications with abuse potential.
Researchers developed an algorithmic approach to diagnosing lung cavitary diseases.
Nivolumab plus ipilimumab linked to better survival in NSCLC with high tumor mutational burden.
Majority of patients say they want to know about even minor consequences of cancer drug substitutions.
Dacomitinib is a pan-human epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.
Findings based on rates in women vs steady decline seen nationally.
An integrated proteomic classifier accurately identified benign lung nodules when used in patients with a pretest probability of malignancy ≤50%.
Independent predictive factors of lung cancer in chronic obstructive pulmonary disease may include frequency of exacerbations, in addition to airflow obstruction and visual emphysema.
Researchers used data from the Atherosclerosis Risk in Communities Study to assess associations between dietary pattern and pulmonary assessments.
During a 10-year period, there was an increase in the rate of commercially insured patients receiving infused chemotherapy in hospital outpatient departments.
Study examines increased physical activity may lower the risk for several cancers and may be beneficial for improving quality of life.
A CHEST expert panel has released updated guidelines for lung cancer screening.
Patients who underwent lung resections had reduced postoperative complication rates when they participated in preoperative exercise.
Mortality rates are higher after surgery vs stereotactic body radiotherapy for patients with early non-small-cell lung cancer.
Lung cancer screening is more effective and efficient for high-risk individuals.
Younger age and higher body mass index may be positive predictors of progression-free survival in patients with squamous cell carcinoma of the lung.
Lack of insurance correlated with a reduced likelihood of chemotherapy and radiation therapy for small cell lung cancer.
Qualitative risk statements of malignancy for indeterminate pulmonary nodules are imprecise, highly variable, and should be replaced by a standard scale.
The cancer death rate declined by 1.5% annually from 2006 to 2015 in the United States.
Lung cancer screening based on USPSTF criteria decreased from 2010 to 2015 while risk-targeted screening is associated with modest gains in terms of early lung cancer mortality per person screened.
Few modern, US FDA-approved immuno-oncology agents have durable survival and response rates that are deemed significant by the ASCO value framework.
Many octogenarians and nonagenarians with non-small cell lung cancer do not receive cancer-directed care.
Platinum-based chemotherapy agents for lung cancer may increase the risk for thromboembolism.
Adjuvant chemotherapy administered prior to, rather than concurrently with, radiotherapy improves survival outcomes among patients with NSCLC.
Few cases of lung cancer suspected in counties with smoke-free ordinances.
Improvements in cancer survival were limited to patients with private insurance, from 1997-2014.
An estimated 42.0% of all incident cancers and 45.1% of cancer deaths in the United States are attributed to potentially modifiable risk factors.
Survival is better with lobectomy than SBRT in patients with NSCLC.
More than 50% of patients report experiencing cancer-related fatigue throughout the disease process.
Three of 13 attributes identified had the highest potential for reduced spending without compromising care.
Patients with PD-L1-positive malignancies have shown higher response rates to immune checkpoint inhibition and consequently prolonged progression-free/overall survival compared with others.
Treatment with osimertinib is associated with longer progression-free survival in patients with previously untreated EGFR mutation-positive advanced non-small-cell lung cancer.
Between 2000 and 2010, researchers identified a decline in the number of patients with stage I NSCLC who remained untreated.
Results of two phase 3 studies found that nivolumab provided superior overall survival vs docetaxel in people with non-small cell lung cancer.
Trial results provided strong evidence against the use of anticoagulant low molecular weight heparin in SCLC.
Patients with lung cancer and atherosclerosis diagnosis may benefit from anti-inflammatory therapy with canakinumab.
Patients with NSCLC experienced improvements in both function and quality of life with yoga therapy.
Study results stress the importance of a multiethnic support system for patients needing to overcome communication barriers.
PanCan study effectively identified patients who eventually developed early-stage lung cancer, compared to other predictive models.
The ACCP just released new lung cancer screening guidelines.
Researchers surveyed knowledge, beliefs, attitudes, barriers, and facilitators related to screening patients for lung cancer.
Pazopanib improves progression-free survival in patients with small-cell lung cancer.
First generation EGFR tyrosine kinase inhibitors should be used in combination with chemotherapy if a patient has progressive EGFR mutation-positive non-small cell lung cancer.
Dacomitinib improved progression-free survival in patients with non-small cell lung cancer.
Tumor lysis syndrome can occur even in the absence of chemotherapy, and clinicians should remain suspicious when patients demonstrate laboratory abnormalities.
Overall and progression-free survival were improved with greater depth of response to therapy in non-small cell lung cancer.
Patients with metastatic lung cancer who receive both both immune checkpoint inhibitors and thoracic radiotherapy.do not have a greater risk for immune-related adverse events.
Adjuvant adoptive cellular immunotherapy plus chemotherapy improved survival in patients with resected non-small cell lung caner.
Thoroughness of nodal examination determines prognostic value of non-small cell lung cancer staging.
ROS1 and ALK rearrangements in patients with non-small cell lung cancer may predict different metastasis distributions at diagnosis.
A new diagnostic test and algorithm may be able to diagnose lung cancer from tumor-educated platelets.
Smokers with HIV who are adherent to antiretroviral therapy are still likely to die from lung cancer.
Higher doses of chemoradiation in stage 3 non-small cell lung cancer did not improve overall survival rates.
There may be a decreased rate of lung cancer for patients who receive anti-inflammatory therapy with canakinumab.
Fewer than 30% of patients undergoing durvalumab therapy experienced either grade 3 or 4 adverse events.
Recommendations to include CT scans as standard follow-up procedure is based on poor evidence.